文献速递淋巴瘤

低剂量维莫非尼联合利妥昔单抗治疗初治及复发难治性毛细胞白血病:Scripps方案

Low-dose vemurafenib plus rituximab in frontline and relapsed or refractory hairy cell leukemia: the Scripps regimen.
PubMed 文献 · Blood Adv · 2026-01-01

该前瞻性观察研究纳入15例初治或复发难治性毛细胞白血病成人患者,采用低剂量维莫非尼(240mg每日两次口服8周)联合利妥昔单抗(375mg/m2静脉每2周一次共14周8剂)治疗。所有患者均获完全血液学恢复,总缓解率87%,完全缓解率73%,6个月时MRD阴性率53%,中位随访18个月时1例进展,无3-4级毒性或死亡。

要点

  • 低剂量维莫非尼联合利妥昔单抗在初治和复发难治HCL中均显示高缓解率和良好耐受性。
  • 所有患者达完全血液学恢复,血小板和中性粒细胞恢复正常中位时间分别为15天和29天。
  • 总缓解率87%,完全缓解率73%,6个月MRD阴性率53%,无3-4级毒性。

核心结论

  • 低剂量维莫非尼联合利妥昔单抗在初治及复发难治性HCL中诱导快速血液学恢复且耐受性良好。

研究设计与样本

  • 前瞻性观察研究,纳入15例初治或复发难治性HCL成人患者。
  • 干预为低剂量维莫非尼240mg每日两次口服8周,联合利妥昔单抗375mg/m2静脉每2周一次共14周8剂。

主要发现

  • 所有患者达完全血液学恢复,血小板>100×10^3/μL和中性粒细胞>1.0×10^3/μL的中位恢复时间分别为15天和29天。
  • 总缓解率87%,完全缓解11例(73%,95%CI 48-89),部分缓解2例。
  • 6个月时MRD阴性8例(53%,95%CI 27-79)。
  • 初治患者(n=7)完全缓解6例(86%,95%CI 42-100),MRD阴性4例(57%,95%CI 18-90)。
  • 复发难治患者(n=8,中位既往治疗1线)完全缓解5例(63%,95%CI 24-91),MRD阴性4例(50%,95%CI 16-84)。

临床怎么用

  • 低剂量维莫非尼联合利妥昔单抗可作为初治及复发难治性HCL的一种高效低毒治疗选择。

局限性

  • 样本量小(15例),为非随机观察性研究,随访时间较短(中位18个月)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Purine nucleoside analogs are highly effective in the treatment of hairy cell leukemia (HCL) but are associated with myelosuppression and immunosuppression. Targeted therapy with the BRAF inhibitor vemurafenib in combination with the anti-CD20 antibody rituximab has shown marked efficacy, but traditional dosing of vemurafenib (960 mg twice daily) requires frequent dose reductions. We conducted a prospective observational study of low-dose vemurafenib (240 mg twice daily orally for 8 weeks) plus rituximab (375 mg/m2 IV every 2 weeks for 14 weeks, 8 total doses) in adults with treatment-naïve or relapsed/refractory HCL. Fifteen patients were enrolled. All achieved complete hematologic recovery, with normalization of thrombocytopenia (platelet count >100 × 103/μL) and neutropenia (neutrophil count >1.0 × 103/μL) at a median of 15 and 29 days, respectively. The overall response rate was 87%, including 11 complete responses (CRs; 73%; 95% confidence interval [CI], 48-89) and 2 partial responses, with 8 patients (53%; 95% CI, 27-79) achieving minimal residual disease (MRD) negativity at 6 months. Frontline patients (n = 7) had 6 CRs (86%; 95% CI, 42-100) and 4 were MRD-negative (57%; 95% CI, 18-90), whereas relapsed/refractory patients (n = 8; median of 1 prior therapy) had 5 CRs (63%; 95% CI, 24-91) and 4 were MRD-negative (50%; 95% CI, 16-84). At a median follow-up of 18 months, 1 patient progressed at 20 months; median progression-free survival was not reached. No grade 3 to 4 toxicities or deaths occurred. Low-dose vemurafenib combined with rituximab induced rapid hematologic recovery and favorable tolerability in patients with both untreated and relapsed/refractory HCL. This trial was registered at www.clinicaltrials.gov as NCT05388123.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Hermel DJ, Saven A. Low-dose vemurafenib plus rituximab in frontline and relapsed or refractory hairy cell leukemia: the Scripps regimen. Blood Adv. 2026. PMID: 42308249. doi:10.1182/bloodadvances.2025019243

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。